Literature DB >> 18577565

Renal haemodynamic and tubular actions of urotensin II in the rat.

Alaa E S Abdel-Razik1, Ellen J Forty, Richard J Balment, Nick Ashton.   

Abstract

Urotensin II (UTS) is a potent vasoactive peptide that was originally identified in teleost fish. Mammalian orthologues of UTS and its receptor (UTSR) have been described in several species, including humans and rats. We have shown previously that bolus injections of UTS caused a decrease in urine flow and sodium excretion rates in parallel with marked reductions in renal blood flow (RBF) and glomerular filtration rate (GFR). The aim of this study was to determine the effect of UTS infusion at a dose that has minimal impact upon renal haemodynamics in order to identify a potential direct tubular action of UTS. Infusion of rat UTS (rUTS) at 0.6 pmol/min per 100 g body weight in male Sprague-Dawley rats, which had no effect on RBF and caused a 30% reduction in GFR, resulted in a significant increase in the fractional excretion of sodium (vehicle 2.3+/-0.6 versus rUTS 0.6 pmol 4.5+/-0.6%, P<0.05) and potassium. At the higher dose of 6 pmol/min per 100 g body weight, haemodynamic effects dominated the response. rUTS induced a marked reduction in RBF and GFR (vehicle 1.03+/-0.06 versus rUTS 6 pmol 0.31+/-0.05 ml/min per 100 g body weight, P<0.05) resulting in an anti-diuresis and anti-natriuresis, but no change in fractional excretion of sodium or potassium. Uts2d and Uts2r mRNA expression were greater in the renal medulla compared with the cortex. Together, these data support an inhibitory action of Uts2d on renal tubule sodium and potassium reabsorption in the rat, in addition to its previously described renal haemodynamic effects.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18577565     DOI: 10.1677/JOE-08-0260

Source DB:  PubMed          Journal:  J Endocrinol        ISSN: 0022-0795            Impact factor:   4.286


  6 in total

1.  In vitro siRNA-mediated knockdown of the UT receptor: implications of density on the efficacy of a range of UT ligands.

Authors:  Benjamin D Hunt; Leong L Ng; David G Lambert
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2012-06       Impact factor: 3.000

2.  Urotensin II levels in patients with chronic kidney disease and kidney transplants.

Authors:  Mehmet Hursitoglu; Tufan Tukek; Mehmet Ali Cikrikcioglu; Osman Kara; Rumeyza Kazancioglu; Oktay Ozkan; Mustafa Cakirca; Fatih Akdogan; Erdal Gundogan; Sengul Aydin; Ismet Beycan; Meltem Gursu; Serkan Dogan; Aybala Erek
Journal:  Ups J Med Sci       Date:  2011-11-18       Impact factor: 2.384

3.  Renal Urotensin II System Plays Roles in the Regulation of Blood Pressure in Dahl Salt-Resistant Rat.

Authors:  Fei Wu; Guanjong Chen; Aihua Zhang; Yang Yu; Minhua Fan; Chaoshu Tang
Journal:  Int J Hypertens       Date:  2016-12-19       Impact factor: 2.420

4.  Urotensin II in the development and progression of chronic kidney disease following ⅚ nephrectomy in the rat.

Authors:  Heather J Eyre; Thomas Speight; Jocelyn D Glazier; David M Smith; Nick Ashton
Journal:  Exp Physiol       Date:  2019-01-15       Impact factor: 2.969

5.  Urotensin-II: More Than a Mediator for Kidney.

Authors:  Ayşe Balat; Mithat Büyükçelik
Journal:  Int J Nephrol       Date:  2012-10-10

6.  The urotensin system is up-regulated in the pre-hypertensive spontaneously hypertensive rat.

Authors:  Ellen J Forty; Nick Ashton
Journal:  PLoS One       Date:  2013-12-05       Impact factor: 3.240

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.